Qualigen therapeutics engages td2 as contract research organization for preclinical development of qn-302

Carlsbad, calif., march 30, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (cro) translational drug development (td2) to lead the preclinical development of lead drug candidate qn-302. qualigen is initially investigating qn-302 for the potential treatment of pancreatic ductal adenocarcinoma (pdac), which represents the vast majority of pancreatic cancers.
QLGN Ratings Summary
QLGN Quant Ranking